Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The immune system is the body's defense against infection and other disease. After
transplantation, the body sees the new organ as "foreign" and tries to destroy or "reject"
it. Immunosuppressive medications help to prevent the immune system from attacking a
transplanted organ. The primary purpose of this study is to investigate the impact of two
maintenance immunosuppressive regimens. Subjects who enroll in this study will be randomly
selected to have tacrolimus and everolimus (group 1) or tacrolimus and mycophenolate mofetil
(group 2) as their immunosuppression medication.
This study will enroll adult patients who are scheduled to receive a kidney transplant.
The study is designed to understand the mechanisms of Everolimus in regards to kidney
function in transplant recipients. The investigators hypothesis is that decreased exposure to
Tacrolimus to the immune system will then translate in better renal allograft function.